PD184161

PD184161 is an orally active MEK inhibitor. PD184161 inhibits MEK activity (IC50=10-100 nM) in a time- and concentration-dependent manner. PD184161 inhibits cell proliferation and induces apoptosis. PD184161 produces depressive-like behavior[1][2].

Product Specifications

CAS Number

[212631-67-9]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis; MEK

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pd184161.html

Purity

98.08

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NOCC1CC1)C2=CC(Br)=C(F)C(F)=C2NC(C(Cl)=C3)=CC=C3I

Molecular Formula

C17H13BrClF2IN2O2

Molecular Weight

557.56

Precautions

H315, H319

References & Citations

[1]Klein PJ, et al. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia. 2006 Jan;8 (1) :1-8.|[2]Gladbach A, et al. ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke. J Neural Transm (Vienna) . 2014 May;121 (5) :543-7.|[3]Duman CH, et al. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry. 2007 Mar 1;61 (5) :661-70.